兰迪洛尔和体内器官衰竭患者:STRESS-L随机临床试验
Tony Whitehouse1,2, Anower Hossain3, Gavin D Perkins1,3
1University Hospitals of Birmingham NHS Foundation Trust, Queen Elizabeth Hospital, Birmingham, United Kingdom.
JAMA
|October 25, 2023
概括
兰迪洛尔输液在患有心跳动的败血症患者中没有改善器官衰竭. 这项研究表明,兰迪洛尔不推用于治疗接受诺亚上腺素治疗的患者的心跳过敏.
科学领域:
- 危急护理医学
- 药理学
- 心血管生理学
背景情况:
- 败血性休克涉及上腺应激影响多个器官系统.
- 贝塔阻塞可以减轻catecholamine的作用,并降低败血症死亡率.
- 慢心病是一种常见的败血症并发症,需要血管压缩剂的支持.
研究的目的:
- 评估兰地的疗效和安全性.
- 在需要长期血管压缩剂治疗的患者中,确定兰迪洛尔是否能降低器官衰竭 (SOFA评分).
主要方法:
- 这是一项开放式的多中心随机试验,对126名患有心力衰竭的成年败血症患者进行试验.
- 参与者接受了标准治疗或兰地醇输注,同时接受了上腺素.
- 主要结果:在14天的时间内,测试器官衰竭 (SOFA) 的平均得分.
主要成果:
- 由于可能的危害和缺乏证明的益处,该试验被提前终止.
- 与标准治疗相比,兰迪洛尔没有显著降低平均SOFA得分 (MD,0. 75;P=. 24).
- 在28天或90天死亡率中没有显著差异;相似的不良事件发生率.
结论:
- 兰迪洛尔输液在接受诺亚上腺素治疗的心跳动患者中没有改善器官衰竭.
- 这些研究结果不支持使用兰迪来控制这种患者群体的心力衰竭.
- 需要进一步的研究来澄清β阻塞剂在败血症冲击治疗中的作用.
更多相关视频
相关概念视频
Heart Failure Drugs: Inotropic Agents
598
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
598
Heart Failure III: Clinical Manifestations
20
Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
20
Heart Failure II: Pathophysiology
14
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
14
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
438
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
438
Heart Failure V: Medical Management
9
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
9
Heart Failure Drugs: β-Blockers
346
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
346


